Related Experiment Video
Updated: Feb 24, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer:
Sandro Pignata1, Giovanni Scambia1, Alessandra Bologna1
1Sandro Pignata, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Laura Arenare, Alice Bergamini, Jane Bryce, Gennaro Daniele, Maria Carmela Piccirillo, and Francesco Perrone, Istituto Nazionale per lo Studio e la Cura dei Tumori-Fondazione G. Pascale, IRCCS; Simona Signoriello and Ciro Gallo, Università degli Studi della Campania Luigi Vanvitelli, Naples; Giovanni Scambia, Domenica Lorusso, Gabriella Ferrandina, and Vanda Salutari, Università Cattolica del Sacro Cuore; Enrico Breda, Ospedale San Giovanni Calibita Fatebenefratelli, Rome; Alessandra Bologna, Azienda Ospedaliea Santa Maria Nuova, IRCCS, Reggio Emilia; Domenica Lorusso and Francesco Raspagliesi, Fondazione IRCCS Istituto Nazionale dei Tumori; Giorgia Mangili and Alice Bergamini, Ospedale San Raffaele, Milan; Viviana Murgia, Ospedale Santa Chiara, Trento; Roberto Sorio, Centro di Riferimento Oncologico, Aviano; Gabriella Ferrandina, Centro di Ricerca e Formazione Ad Alta Tecnologia nelle Scienze Biomediche, Università Cattolica del Sacro Cuore, Campobasso; Cosimo Sacco, Azienda Ospedaliera di Perugia Santa Maria della Misericordia, Udine; Gennaro Cormio, Ginecologia Oncologica, Università di Bari e Istituto Oncologico "Giovanni Paolo II" Bari; Saverio Cinieri, Ospedale Antonio Perrino, Brindisi; Donato Natale, Ospedale San Massimo, Penne, Italy; Ignace B. Vergote, University Hospital Leuven and Belgian and Luxembourg Gynaecological Oncology Group, Leuven Cancer Institute, Leuven, Belgium; and Uwe Wagner, Uniklinkum Giessen und Marburg Gynäkologie, Marburg, Germany.
Abstract:
Purpose Platinum-based chemotherapy (PBC) for patients with progressing ovarian cancer (OC) is more effective with a longer time interval from previous platinum treatment (platinum-free interval [PFI]). In 1999, it was hypothesized that prolonging PFI with single-agent non-PBC (NPBC) may offer a strategy to improve overall outcome. MITO-8 aimed to verify this hypothesis commonly used in clinical practice although it has not been prospectively tested. Methods MITO-8 is an open-label, prospective, randomized, superiority trial. Patients with OC who experienced disease progression 6 to 12 months after their last platinum treatment were randomly assigned 1:1 to the experimental sequence of NPBC followed by PBC at subsequent relapse or the standard reverse treatment sequence. Overall survival (OS) was the primary end point. Results Two hundred fifteen patients were enrolled (standard arm [n = 108]; experimental arm [n = 107]). The trial ended before planned because of slow enrollment. PFI was prolonged in the experimental arm (median, 7.8 v 0.01 months). There was no OS benefit in the experimental arm (median, 21.8 v 24.5 months; hazard ratio, 1.38; 95% CI, 0.99 to 1.94; P = .06). Progression-free survival after the sequence was significantly shorter in the experimental arm (median, 12.8 v 16.4 months; hazard ratio, 1.41; 95% CI, 1.04 to 1.92; P = .025). Global quality-of-life change after three cycles was worse in the experimental arm. Slight differences were observed in the incidence of adverse effects. Conclusion MITO-8 supports the recommendation that PBC not be delayed in favor of an NPBC in patients with partially platinum-sensitive OC. PBC should be used as a control arm in future trials of new drugs in this setting.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:54Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
